Parathyroid hormone (PTH) has a significant role as an anabolic hormone in bone when administered by intermittent injection. Previous microarray studies in our laboratory have shown that the most highly regulated gene, monocyte chemoattractant protein-1 (MCP-1), is rapidly and transiently induced when hPTH(1-34) is injected intermittently in rats. Through further in vivo studies, we found that rats treated with hPTH(1-34) showed a significant increase in serum MCP-1 levels 2 hours after PTH injection compared to basal levels. Using immunohistochemistry, increased MCP-1 expression in osteoblasts and osteocytes is evident after PTH treatment. PTH also increased the number of marrow macrophages. MCP-1 knockout mice injected daily with hPTH(1-34) showed less trabecular bone mineral density and bone volume compared to wild type mice as measured by pQCT and microCT. Histomorphometric analysis revealed that the increase in osteoclast surface and osteoclast number observed with intermittent PTH treatment in the wild type mice was completely eliminated in the MCP-1 null mice, as well as much lower numbers of macrophages. Consequently, the lack of osteoclast and macrophage activity in the MCP-1 null mice was paralleled by a reduction in bone formation. We conclude that osteoblast and osteocyte MCP-1 expression is an important mediator for the anabolic effects of PTH on bone.
Introduction
Parathyroid hormone (PTH) is the major hormone regulating calcium homeostasis, but it also has a significant role in bone remodeling. Bone remodeling is a coordinated and highly regulated process of bone resorption and bone formation necessary for maintaining bone health. PTH has a dual effect on bone turnover depending on the mode of administration. When given as intermittent injections, PTH stimulates bone remodeling with a net increase in bone formation, but continuous infusion causes bone loss (1) (2) (3) (4) . The anabolic effects of parathyroid hormone are well documented in both animal and human studies (5) (6) (7) (8) . Recombinant human parathyroid hormone is currently used as a treatment for osteoporosis (9) (10) . The mechanisms of this contradictory effect are not completely understood, although it has been established that osteoclastic resorption is necessary for the bone anabolic effect of PTH (11) (12) (13) . Mature osteoclasts are formed by the fusion of precursor cells of the monocyte/macrophage lineage. The PTH receptor (PTH1R) is located on the osteoblast (14) , as well as stromal cells, osteoblast progenitors and osteocytes. PTH-stimulated osteoclastic resorption is mediated through factors expressed by the osteoblast lineage cells, and osteocytes have been shown to be a major target of PTH-stimulated bone remodeling (15) (16) (17) .
There are many known genes that are regulated by both intermittent and continuous administration of PTH (18) (19) . In our laboratory (20) (21) , microarray studies and mRNA from 3 month old female rats treated with intermittent human PTH showed that the chemokine, monocyte chemoattractant protein-1 (MCP-1, CCL2), was the most highly induced gene (100-250 fold). RT-PCR of RNA isolated from femurs of rats treated with hPTH(1-34) for 14 days showed that MCP-1 mRNA induction was very rapid, but transient, with maximal expression 1 hour after PTH injection. In UMR 106-01 cells, MCP-1 mRNA levels increased 20 fold around 90 minutes after hPTH(1-34) treatment, and MCP-1 secreted protein levels peaked 2 hours after treatment. MCP-1 increased 1 hour after hPTH(1-34) treatment in primary calvarial osteoblastic cells in the differentiation, proliferation and mineralization stages. Osteoclastogenesis is induced by receptor activator of nuclear factor kappa beta ligand (RANKL) and macrophage stimulating factor (M-CSF). The addition of MCP-1 to primary cultures containing M-CSF and RANKL significantly increased tartrate resistant acid phosphatase (TRAP) mRNA expression, pre-osteoclast differentiation and fusion (21) .
Chemokines are small proteins that function primarily to direct the movement of circulating leukocytes and monocytes to sites of infection, inflammation, trauma and ischemia. Recruitment of leukocytes in response to inflammatory stimuli is crucial for the cellular and adaptive immune responses.
Chemokines are divided into four main subfamilies (C, CC, CXC and CX3C) based on the location of the N-terminal cysteine residues. MCP-1, also known as CCL2, is a member of the CC subfamily of chemokines. Chemokines selectively activate leukocyte subpopulations. The principal function of MCP-1 is to stimulate monocyte and macrophage recruitment. MCP-1 predominantly initiates signal transduction through binding a G-protein coupled receptor CCR2 (22) . Monocytes express CCR1, CCR2 and CCR5, but MCP-1 binds only to CCR2 with high affinity (23) . A close association exists between the immune system and the skeletal system. Immune cells and hematopoietic stem cells are found in the bone marrow where they interact with bone cells and the two systems share a number of regulatory molecules including cytokines, receptors, signaling molecules and transcription factors (24) .
MCP-1 is detected at the site of tooth eruption and it is implicated in the pathogenesis of inflammatory conditions characterized by monocyte cell infiltration such as bacterial infection, atherosclerosis, rheumatoid arthritis and bone metastasis. Osteoblasts are the principal cells expressing MCP-1 in inflamed bone, and there is a significant correlation between MCP-1 positive cells and recruitment of monocytes and macrophages (25) .
MCP-1 and CCR2 knockout mice both exhibit a deficiency in monocyte recruitment in response to inflammatory conditions (23, 26) . Analysis of the bone phenotype of CCR2 -/-mice showed increased cortical BMD but less trabecular bone in lumbar spine and distal femur. They also showed less increase in bone volume after intermittent PTH treatment indicating signaling through CCR2 mediates the anabolic effect of PTH (27) . In contrast another group reported CCR2 -/-mice have increased BMD and trabecular bone content attributed to a decrease in osteoclast development. Furthermore, ovariectomized CCR2 -/-mice were also protected from osteoporosis (28) . Even though the CCR2 receptor is the primary receptor for MCP-1, it can also bind other CC chemokines (29) (30) . Thus, to determine which chemokine is important in PTH's anabolic actions, we investigated the bone phenotype and effects of PTH treatment in MCP-1 -/-mice. We found that MCP-1 expression is necessary for osteoclast and macrophage recruitment, osteoclast formation and bone resorption associated with PTH anabolic effects.
Materials and Methods

Animals
All animals were maintained under conditions of a 12 hour light/dark cycle with standard rodent chow and water ad libitum. The Institutional Animal Care and Use Committee at UMDNJ-Robert Wood Johnson Medical School (Piscataway, NJ) approved all treatments and procedures.
Serum MCP-1 in Rats
Male Sprague-Dawley rats 4 months of age were obtained from Harlan Laboratories (Indianapolis, IN). Rats were lightly anesthetized with isoflurane (Baxter, Deerfield, IL) and blood was collected from the lateral tail vein. Serum MCP-1 levels were measured by ELISA using the rat MCP-1 ELISA kit from Invitrogen (Carlsbad, CA). MCP-1 concentrations from rat samples were determined from a standard curve constructed using curve fitting software (four parameter algorithm). Minimal detectable concentration of MCP-1 is < 8.0 pg/ml, assay precision: CV = 5.7% intra-assay; 8.5% inter-assay. Rats were treated with hPTH(1-34) sc (Millipore, Billerica, MA) or vehicle (saline) injections.
Time Course: Four month old male rats (n = 10 per group) were treated with daily injections of vehicle (saline) or hPTH at 80 µg/kg for 14 days. Blood samples were collected between 0-6 hours on day 14 of treatment.
Dose Effect and Duration of Treatment: Four month old male rats (n = 5 per group) were treated with daily injections of vehicle (saline) or hPTH(1-34) at 40 or 80 µg/kg for up to 14 days. Blood samples were collected 2 hours post-dose after 1, 7 and 14 days of treatment.
Gender Effects: Four month old male and female rats (n = 5 per group) were treated with daily injections of vehicle (saline) or hPTH at 80 µg/kg for 28 days. Blood samples were collected before beginning treatment and again 2 hours after injection on day 28 of treatment.
Immunohistochemistry
Rat Bone: Tibiae were collected 2 hours post-dose on days 1-3, 7 and 14 of treatment. Tibiae were fixed in 10% neutral buffered formalin, decalcified in 10% EDTA, then processed through graded ethanols, cleared in xylene and embedded in paraffin. Sections (5 µm) were cut on a Shandon Finesse microtome (Thermo-Fisher Scientific, Waltham, MA) and collected on slides. For MCP-1 IHC, the sections were deparaffinized, rehydrated and immunostained with a 1:50 dilution of anti-rat MCP-1 antibody or isotype control (Millipore, Billerica, MA) with the HistoMouse Max DAB detection kit (Invitrogen, Carlsbad, CA). Sections were first blocked in blocking reagent. Primary antibodies were incubated at room temperature for 60 minutes followed by incubation with secondary antibody for 10 minutes. DAB chromogen for MCP-1 detection was applied for 3 minutes then counterstained with hematoxylin for 1 minute.
For CD68[ED-1] IHC, additional sections were deparaffinized and rehydrated followed by antigen retrieval in 0.37% trypsin for 10 minutes at 37°C. Sections were immunostained with a 1:50 dilution of anti-rat CD68 [ED-1] (Millipore) or isotype control with HistoMouse Max AEC detection kit (Invitrogen). Sections were first blocked in blocking reagent. Primary antibodies were incubated at room temperature for 60 minutes followed by a 10 minute incubation with secondary antibody. AEC chromogen for CD68 detection was applied for 10 minutes and the sections were counterstained with hematoxylin for 1 minute. Analysis of monocyte/macrophage number was done using a BioQuant image analysis system (Nashville, TN). CD68[ED-1] positive cells were counted in the secondary spongiosa between trabeculae. Osteoclasts and multinucleated cells were not included in the cell count. A total of 36 fields at 100X magnification were measured.
Mouse Bone: Tibiae were collected 2 hours post-dose after 6 weeks of treatment which was administered 5 days per week. The samples were processed and immunostained for MCP-1 as described above for rats. For F4/80 and MAC-3, the sections were treated similarly to the MCP-1 sections with a 1:300 dilution of anti-mouse F4/80 or MAC-3 antibody or isotype control (Serotec, Oxford, UK). Primary antibodies were incubated at room temperature for 60 minutes followed by incubation with secondary biotinylated antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:200 dilution and streptavidin (Dako, Carpinteria, CA) at 1:300 dilution for 30 minutes each. AEC chromogen for F4/80 and MAC-3 detection was applied for 5 minutes then counterstained with hematoxylin for 1 minute.
Bone Effects of PTH in MCP-1 Null Mice
Breeding pairs of MCP-1 -/-mice and wild type controls (C57/BL6) were purchased from The Jackson Laboratory (Bar Harbor, ME) and colonies were established and crossed for 10 generations. The genotypes of pre-weanling mice were confirmed by PCR following the Jackson Laboratory genotyping protocol. Male and female wild type and MCP-1 -/-mice at 4 months of age (n = 12 per group) were treated with daily injections of vehicle (saline) or hPTH at 80 µg/kg sc 5 days per week for 6
weeks. Mice at 6 months of age (n = 8 per group) were also treated in the same manner. All animals were injected with 15 mg/kg calcein (Sigma, St. Louis, MO), 9 and 2 days prior to necropsy. Tibiae were excised, one was processed for histology, and the other was used for ex-vivo peripheral quantitative computed tomography (pQCT) and micro-computed tomography (μCT) analysis of trabecular bone architecture. One femur was also collected for pQCT analysis of cortical bone.
Peripheral Quantitative Computed Tomography (pQCT)
The total and trabecular bone mineral density (BMD) of the proximal tibia was evaluated using an XCT Research SA (Norland/Stratec Medizintechnik, Pforzheim, Germany). After running a scout scan for a length of 10 mm, the pQCT scan was initiated 1.4 mm distal from the proximal epiphysis. The scan is 1 mm thick with a voxel size of 90 μm. Using an iterative algorithm, soft tissue (density below 223 mg/cm 3 ) was automatically removed and the density of the remaining bone reported as total density (mg/cm 3 ). A concentric peel of the outer 55% of the bone was used to determine trabecular density (mg/cm 3 ). Cortical BMD was measured on the femur. The femur length was determined after a scout scan was run for the full length of the bone. The pQCT scan was initiated at the mid-diaphysis of the femur. The scan is 1 mm thick with a voxel size of 90 μm. Using an iterative algorithm, tissue with density below 500 mg/cm 3 was automatically removed. The density of the remaining bone is reported as cortical density (mg/cm 3 ). The analysis software was also used to determine cortical thickness (Ct.Th), periosteal perimeter (Ps.Pm) and endocortical perimeter (Ec.Pm).
Micro-Computed Tomography (μCT)
Measurements of trabecular architecture were done on the proximal tibia metaphysis using a μCT 20 Quantitative histomorphometry was done using a BioQuant image analysis system (Nashville, TN).
Fifty fields in the secondary spongiosa at 40X were quantified. Static histomorphometry was measured 
Statistical Analysis
Data were analyzed by Dunnett's one-way analysis of variance (ANOVA) or two-way ANOVA followed by Tukey's multiple comparison test using SigmaStat software (SPSS Sciences, Chicago IL).
Data are expressed as the mean ± standard error with p < 0.05 considered significant.
Results
Effect of PTH on Serum MCP-1 Levels in Rats
Since the induction of MCP-1 mRNA in rats injected with PTH was so profound (100-250 fold 1 hour after injection) we were interested in assessing if this was reflected in changes in serum levels of MCP-1. The time course and dosing duration used to examine serum MCP-1 were modeled after the treatment regimen used in our in vivo mRNA work, which followed the anabolic protocols for rats developed previously by others (2, 19) . To determine the time point where maximal serum levels of MCP-1 are achieved after injection with PTH, rats were injected daily with 80 μg/kg hPTH(1-34) sc for 14 days and serial blood samples were collected after the last injection. Results show that peak serum MCP-1 levels occur 2 hours after PTH injection with levels approaching baseline by 4 hours ( Figure 1A ). There was a 1.5-2 fold increase in serum MCP-1 levels two hours after PTH injection compared to basal levels.
The dose response of PTH treatment and the effect of the duration of PTH treatment on serum MCP-1 levels were further investigated. Rats were injected daily with vehicle (saline), 40 μg/kg or 80 μg/kg hPTH(1-34) sc for 14 days. Blood was collected 2 hours after injection on Days 1, 7 and 14. Figure 1B shows that with the 40 μg/kg dose of hPTH(1-34) serum MCP-1 levels increase in comparison to vehicle treated animals with the magnitude of the increase dependent on the duration of PTH treatment. MCP-1 levels increased by 24%, 53% and 79% compared to vehicle on days 1, 7 and 14
respectively. In contrast 80 μg/kg of hPTH(1-34) produced a maximal increase in serum MCP-1 from the first injection and no further increase was observed with duration of treatment. A previous study with hPTH at doses of 40, 80 and 120 μg/kg showed that maximum serum levels of MCP-1 were attained at the 80 μg/kg dose and no further increase was observed with a higher dose of PTH (data not shown).
Possible gender differences in serum MCP-1 levels were examined after a one month treatment period with PTH. In addition we were also interested to see if the increase in serum MCP-1 was maintained with an extended duration of PTH treatment. Male and female rats (n = 6/group) were injected daily with vehicle (saline) or 80 μg/kg hPTH(1-34) sc for 28 days. Serum samples were analyzed for MCP-1 at baseline before treatment began and again on day 28 two hours after the last hPTH(1-34) injection.
Serum MCP-1 levels in the vehicle groups treated for 28 days were not different from the baseline levels before treatment began. Two hours after PTH treatment on day 28 serum levels increased 2 fold in both males and females. Serum levels in the female rats were 40-50% less than male rats at baseline and after treatment ( Figure 1C) . Overall, these data provide quantitative proof that MCP-1 protein is increased by PTH in vivo.
Immunohistochemistry of Tibiae in PTH-Treated Rats
In an effort to determine if osteoblasts express MCP-1 in response to PTH in vivo, bone samples were processed for immunohistochemistry to detect the chemokine. Rats were injected daily with vehicle 
Bone Mineral Density of MCP-1 -/-Mice Treated with PTH
To further investigate the role of MCP-1 in the anabolic action of PTH in vivo, four month old male wild type (C57/BL6) mice and MCP-1 -/-mice were injected with either vehicle (saline) or hPTH(1- Figure   3A ) showed that PTH treatment significantly increased both total and trabecular bone mineral density There are no differences between the wild type mice and MCP-1 -/-mice treated with vehicle. Overall the effect of PTH on BMD was blunted in the MCP-1 null mice compared to wild type mice, suggesting that MCP-1 is necessary for the PTH anabolic effect.
The cortical bone compartment was relatively unaffected by the absence of MCP-1. The BMD and cortical thickness significantly increased in PTH-treated wild type and MCP-1 -/-mice compared to the corresponding vehicle treated mice. There were no differences in femur length or endocortical perimeter. Periosteal perimeter was significantly increased in the PTH-treated wild type mice but not in the PTH-treated MCP-1 -/-mice ( Table 1) .
The C57/B6 mouse strain is skeletally mature at 4 months of age, however peak bone mass may not be achieved until 6 months of age (34) . To assess the effect of the anabolic response of PTH on older animals, six month old male wild type and MCP-1 -/-mice were also treated with vehicle or hPTH(1-34), 80 μg/kg sc 5 days per week for six weeks. The same trends observed in the 4 month old mice were also seen in the 6 month old mice. In fact, the 6 month old PTH-treated MCP-1 -/-mice showed significantly lower total, trabecular and cortical BMD compared to the PTH-treated wild type mice.
However, the increases in cortical thickness did not reach statistical significance (Table 2) .
Differences between female PTH-treated wild type and MCP-1 -/-mice are not as evident as in the male mice. Female mice treated from 4 months of age (Supplementary Figure 1 ; Supplementary Table   1 ) and 6 months of age (Supplementary Table 2 ) show some of the same trends seen with the male animals, e.g., a lack of an increase in total and trabecular BMD in the female MCP-1 -/-mice. Lower bone mass (7-10 % bone volume for 4 month old females compared to 13-16% bone volume for males at the same age) and the influence of estrogen may be contributing factors in the smaller changes observed in female mice.
Trabecular Architecture of MCP-1 -/-Mice Treated with PTH
Structural analysis of the trabecular bone of the 4 month old male mice by microCT confirms the results seen by pQCT. Compared to vehicle treatment, trabecular bone volume increased by 27 % in wild type mice treated with PTH whereas no increase was observed in PTH-treated MCP-1 null mice ( Figure 3B ).
PTH also significantly increased trabecular thickness in PTH-treated wild type mice, but very little change was seen in MCP-1 -/-mice treated with PTH compared to the vehicle-treated animals. No significant differences were noted in trabecular number or trabecular separation (Table 3) . Similar trends were also seen in 4 month old female mice, however no changes in trabecular thickness were observed (Supplementary Table 3 ). It appears that the increased bone volume after PTH treatment in male wild type mice is achieved by increasing trabecular thickness; a process that is absent in the male MCP-1 null mice.
Histomorphometry of MCP-1 -/-Mice Treated with PTH
Histomorphometric analysis of the 4 month old male mice revealed that bone area (B.Ar/Tt.Ar) ( Figure   4A ) was significantly increased in the PTH-treated wild type mice compared to vehicle-treated mice Table 4 ).
Immunohistochemistry of Tibiae in PTH-Treated MCP-1 Null Mice
Tibial sections of wild type and MCP-1 -/-mice treated from 4 months of age were immunostained for showed a ramping up of serum levels with increasing duration of treatment while higher doses (80 μg/kg) produced maximal serum levels of MCP-1 after one injection that did not change with increased duration of treatment. There is a positive association between serum MCP-1 levels and serum PTH levels as demonstrated in our study where serum MCP-1 levels tended to be greater in women with higher than normal serum PTH levels (35) . In the present study we have not determined if the major source of the serum MCP-1 levels is from bone since other tissues produce and secrete MCP-1, most notably adipose tissue (36) . However, the rapid response and clear correlation with the time course of mRNA levels seen in the bones of rats injected with PTH supports the notion that the increased MCP-1 is derived from PTH action on cells of the osteoblast lineage. We have also shown that gender differences are apparent in that female rats have lower basal levels of serum MCP-1 than male rats, as well as after treatment with PTH, suggesting that MCP-1 may be modulated by estrogen.
Studies in both humans and animals have shown that estradiol suppresses MCP-1 expression (37-39).
In all, these studies provide quantitative evidence that MCP-1 is increased by PTH.
We performed immunohistochemistry to identify the cells in bone that produce MCP-1 in response to PTH treatment. Increased MCP-1 protein expression is evident in osteoblasts after the second PTH injection with maximal expression by the third injection in rats. We also observed production of MCP-1 in some osteocytes. Others have shown that MCP-1 is produced by osteoblasts in vivo (25, (40) (41) . Table 2 . Bone mineral density of the proximal tibia and cortical parameters of the mid-shaft femur measured by pQCT in male mice treated with or without PTH for 6 weeks from 6 months of age. 
MCP-1 is produced by a variety
